The treatment of patients with hepatic encephalopathy: Review of the latest data from EASL 2010 - Commentary

Gastroenterology and Hepatology

Volumn 6, Issue 7 SUPPL. 11, 2010, Pages 13-14

  Mullen, Kevin D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEOMYCIN; PLACEBO; RIFAXIMIN;

CLINICAL TRIAL; ENZYME INHIBITION; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MEDICAL LITERATURE; MEDICAL RESEARCH; NOTE; PSYCHOMETRY; PUBLICATION; QUALITY OF LIFE;

EID: 77955614734     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. Sanyal A, Bass N, Mullen K, et al. Rifaximin treatment improved quality of life in patients with hepatic encephalopathy: results of a large, randomized, placebo-controlled trial. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 15.
2. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081.
3. Bajaj J, Heuman DM, Schubert C, et al. Persistent deficity in learning of response inhibition following onset of overt hepatic encephalopathy in cirrhosis. Program and abstracts of the 45th Annual Meeting of the European Association for rhe Study of the Liven April 14-18, 2010; Vienna, Austria 2010; Abstract 149.
4. Bajaj J, Schubert C, Sanyal AJ, Bell D, Pisney L, Heuman DM. Severity of chronic cognitive impairment in cirrhosis increases with number of episodes of overt hepatic encephalopathy. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 150.
5. Diaz-Herrero MM, del Campo JA, Carbonero P, et al. THDP-17 inhibits the glutaminase activity in Caco-2 cell cultures. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver, April 14-18, 2010; Vienna, Austria 2010; Abstract 161.
6. Pasquale C, Ridola L, Pentassuglio I, et al. Minimal hepatic encephalopathy (MHE): Simplified diagnosis and relationships with the development of overt hepatic encephalopathy (OHE). Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 185.
7. Randolph C, Bajaj J, Sheikh MY, et al. Mild hepatic encephalopathy (HE) assessed by the Repeatable Battery for the Assessment Neuropscyological Status (RBANS) is highly prevalent in ambulatory patients with cirrhosis. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 189.
8. Sanyal A, Bass N, Poordad F, et al. Rifaximin decreases venous ammonia concentrations and time-weighted average ammonia concentrations correlate with overt hepatic encephalopathy (HE) as assessed by Conn Score in a 6-months study. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 195.
9. Tsushima M, Tsushima W, Tsushima V, et al. A case control study of IMPACT: a brief and effective web-based neuropsychological assessment battery to diagnose minimal hepatic encephalopathy (MHE). Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 202.
10. Grande L, Jover M, Fobelo M, et al. Double-blind crossover trial analyzing the usefulness of rifaximin in the treatment of minimal hepatic encephalopathy (MHE): an interim analysis. Program and abstracts of the 45th Annual Meeting of the European Association fot the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 513.
11. Schranz M, Krismer F, Roos J, et al. Saccadic latency as an objective and quantitative marker of hepatic encephalopadiy. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 536.
12. Garcia-Martinez R, Jacas C, Alonso J, Vargas V, Simon-Talero M, Cordoba J. Prior hepatic encephalopathy and alcohol etiology determine cognitive function after liver transplantation. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria 2010; Abstract 810.